Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC Immunotherapy Combo Wins Big on PFS in First-Line Mets CRC

First-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news